SEC Form 4 · accession 0001140361-15-045998
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Aryeh
Director
Period of report
Dec 29, 2015
Accepted (ET)
Dec 30, 2015 · 8:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Dec 29, 2015 | P | 18,000 | $2.50 | A | 461,078 | I | By JALAA Equities, LP |
| Common SharesF1 | Dec 29, 2015 | P | 400 | $2.49 | A | 461,478 | I | By JALAA Equities, LP |
| Common Shares | holding | — | — | — | 74,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities are owned by JALAA Equities, LP, of which Jason Aryeh is the General Partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, Mr. Aryeh may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.